Our study successfully generated CD19/CD20 dual-targeted CAR-NK cells for combating ALL, thereby reducing the risk of tumor escape resulting from tumor antigen heterogeneity, down-regulation, or loss of antigen expression in ALL. This evidence concerns the gene CD19 and neoplasm.